What's Happening?
Scientists at Northwestern University have discovered that the FDA-approved drug levetiracetam, commonly used as an antiseizure medication, may slow the progression of Alzheimer's disease. The research indicates that levetiracetam prevents the formation
of amyloid-beta 42, a toxic protein associated with Alzheimer's, by altering the processing of amyloid precursor protein (APP). This discovery was made through studies on animal models, human neurons, and brain tissue from high-risk patients. The findings suggest that levetiracetam could delay the onset of Alzheimer's symptoms if administered early, potentially offering a preventative approach to the disease.
Why It's Important?
This research is crucial as it identifies a new use for an existing drug, potentially offering a cost-effective treatment option for Alzheimer's. With nearly 7 million Americans affected by Alzheimer's, a drug that can delay disease progression could significantly impact public health. The study also highlights the importance of early intervention, suggesting that high-risk individuals could benefit from starting treatment well before symptoms appear. This could lead to a shift in how Alzheimer's is managed, focusing more on prevention rather than treatment after onset.
What's Next?
The research team plans to explore the use of levetiracetam in patients with genetic forms of Alzheimer's, including those with Down syndrome, who are at high risk of early onset. Further studies will aim to refine the drug's formulation to enhance its efficacy and longevity in the body. Clinical trials will be necessary to confirm these findings in a broader patient population and to determine the optimal timing and dosage for preventative treatment.
